Buscar
Mostrando ítems 1-6 de 6
Artículo
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
(Wiley-Blackwell, 2021)
Background and objectives The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements ...
Artículo
Sentinel lymph node biopsy vs. Observation in thin melanoma: A multicenter propensity score matching study
(MDPI, 2021)
The therapeutic value of sentinel lymph node biopsy (SLNB) in thin melanoma remains controversial. The aim of this study is to determine the role of SLNB in the survival of thin melanomas (≤1 mm). A multicenter retrospective ...
Artículo
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
(Nature Research, 2021-12-01)
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an ...
Artículo
Clinical practice guideline on melanoma from the Spanish Academy of Dermatology and Venereology (AEDV)
(Elsevier España, 2021)
Specialist approaches to the diagnosis and treatment of melanoma have undergone many changes. This guideline aims to provide Spanish dermatologists with evidence-based information for resolving the most common doubts ...
Artículo
SEOM clinical guideline for the management of cutaneous melanoma (2020)
(Springer Nature, 2021)
Melanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to ...
Artículo
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study
(American Association for Cancer Research, 2021)
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients ...